Company profile

Gubra

Science of certainty

Industry
Biotechnology Research
Employees
330
Headquarters
Hoersholm
Founded
2008
Office locations
1

Gubra company summary

Gubra is a company in the Biotechnology Research industry, headquartered in Hoersholm, founded in 2008. On LinkedIn the company has around 330 employees. Its listed specialties include in vivo pharmacology, histology, stereology, diabetes, obesity.

What technology does Gubra use?

No technologies detected yet. Warmrank rechecks company websites on a rolling basis.

About Gubra

Gubra is a biotech company built on three synergistic business units, Biotech, CRO Services, and Ventures, united by a commitment to scientific excellence, strong partnerships, and responsible impact. ESG principles are embedded in our business model, including Gubra Green, our subsidiary that allocates 10% of pre-tax profits to support a net-zero, nature-positive future. Founded in 2008, Gubra has grown from a metabolic research specialist into a diversified organization of more than 300 scientists and experts. Today, we advance proprietary therapeutic programs, deliver high-end preclinical research services to global partners, and create new drug discovery opportunities through agile venture structures. Our Biotech unit develops a growing pipeline of peptide-based therapeutics targeting metabolic diseases. Lead obesity programs include partnered assets ABBV-295 (a long-acting amylin analogue) and BI 3034701 (a triple agonist). Our internal lead candidate, GUB-UCN2, is a next-generation peptide for healthy weight loss now progressing in clinical development. Our specialized preclinical CRO provides world-class capabilities across in vivo pharmacology, ex vivo assays, peptide chemistry, molecular pharmacology, histology, stereology, AI-enhanced imaging, and bioinformatics. Gubra is recognized for deep expertise in metabolic diseases and for highly translatable preclinical models. Through Gubra Ventures, we develop high-potential science with clear translational hypotheses. Focusing on novel modalities in our core therapeutic areas, we target high-value disease segments where our peptide expertise creates competitive advantage. These focused, flexible structures enable promising programs to progress rapidly while staying closely connected to our scientific foundation. Guided by science, speed, and a commitment to doing business in the best way for people and the planet, we bring together biotech innovation, world-class research, and entrepreneurial venturing.

Specialties

in vivo pharmacologyhistologystereologydiabetesobesityGastrointestinal diseasespeptide chemistrymolecular pharmacologynext generation sequencingbioinformaticsex vivo assaysImagingMASH

Where is Gubra located?

Gubra lists 1 location.

Hoersholm, 2970, DKHQ
Hørsholm Kongevej 11b

Compare companies similar to Gubra

More companies in Biotechnology Research.

CompanyIndustryEmployeesFoundedHeadquarters
Gubra
gubra.dk
Biotechnology Research3302008Hoersholm
Thermo Fisher Scientific
thermofisher.com
Biotechnology Research100,779-Waltham, MA
Amgen
amgen.com
Biotechnology Research41,0281980Thousand Oaks, CA
Biogen
biogen.com
Biotechnology Research7,742-Cambridge, MA
Biocon
biocon.com
Biotechnology Research11,902-Bangalore, Karnataka
Biotechnology Research28,679-Bethesda, MD
Genentech
gene.com
Biotechnology Research18,2961976South San Francisco, California
Eurofins
eurofins.com
Biotechnology Research24,928-Luxembourg, Luxembourg
Gilead Sciences
gilead.com
Biotechnology Research14,743-Foster City, CA
Syneos Health
syneoshealth.com
Biotechnology Research23,772-Morrisville, NC
Moderna
modernatx.com
Biotechnology Research6,2382010Cambridge, Massachusetts

Frequently asked questions about Gubra

What does Gubra do?

Gubra is a biotech company built on three synergistic business units, Biotech, CRO Services, and Ventures, united by a commitment to scientific excellence, strong partnerships, and responsible impact. ESG principles are embedded in our business model, including Gubra Green, our subsidiary that allocates 10% of pre-tax profits to support a net-zero, nature-positive future. Founded in 2008, Gubra has grown from a metabolic research specialist into a diversified organization of more than 300 scientists and experts. Today, we advance proprietary therapeutic programs, deliver high-end preclinical research services to global partners, and create new drug discovery opportunities through agile venture structures. Our Biotech unit develops a growing pipeline of peptide-based therapeutics targeting metabolic diseases. Lead obesity programs include partnered assets ABBV-295 (a long-acting amylin analogue) and BI 3034701 (a triple agonist). Our internal lead candidate, GUB-UCN2, is a next-generation peptide for healthy weight loss now progressing in clinical development. Our specialized preclinical CRO provides world-class capabilities across in vivo pharmacology, ex vivo assays, peptide chemistry, molecular pharmacology, histology, stereology, AI-enhanced imaging, and bioinformatics. Gubra is recognized for deep expertise in metabolic diseases and for highly translatable preclinical models. Through Gubra Ventures, we develop high-potential science with clear translational hypotheses. Focusing on novel modalities in our core therapeutic areas, we target high-value disease segments where our peptide expertise creates competitive advantage. These focused, flexible structures enable promising programs to progress rapidly while staying closely connected to our scientific foundation. Guided by science, speed, and a commitment to doing business in the best way for people and the planet, we bring together biotech innovation, world-class research, and entrepreneurial venturing.

How many employees does Gubra have?

Gubra has around 330 employees on LinkedIn.

Where is Gubra headquartered?

Gubra is headquartered in Hoersholm.

When was Gubra founded?

Gubra was founded in 2008.

Build a lead list from companies like Gubra

Describe your ICP or import a CSV. Warmrank finds matching companies, enriches contacts with verified emails, and tracks every lead.